Hikma Pharmaceuticals (LON:HIK) Price Target Raised to GBX 2,025

Hikma Pharmaceuticals (LON:HIK) had its price target hoisted by Jefferies Financial Group from GBX 1,870 to GBX 2,025 in a research report sent to investors on Tuesday, MarketBeat Ratings reports. The brokerage currently has a buy rating on the stock.

Other equities research analysts have also issued research reports about the company. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating and issued a GBX 1,950 price target on shares of Hikma Pharmaceuticals in a research note on Friday, August 7th. Berenberg Bank boosted their price objective on Hikma Pharmaceuticals from GBX 1,800 to GBX 2,100 and gave the company a “buy” rating in a research report on Tuesday, August 11th. Finally, Citigroup upped their price objective on Hikma Pharmaceuticals from GBX 1,700 to GBX 1,870 and gave the stock a “buy” rating in a research note on Wednesday, August 12th. Six equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of GBX 2,085.83.

Hikma Pharmaceuticals Stock Performance

HIK opened at GBX 1,628 on Tuesday. The firm has a market cap of £3.40 billion, a P/E ratio of 8.99, a PEG ratio of 2.38 and a beta of 0.66. Hikma Pharmaceuticals has a 1-year low of GBX 1,187 and a 1-year high of GBX 1,865. The company has a 50 day simple moving average of GBX 1,585.16 and a two-hundred day simple moving average of GBX 1,461.13. The company has a debt-to-equity ratio of 77.57, a current ratio of 1.98 and a quick ratio of 1.27.

Insider Buying and Selling at Hikma Pharmaceuticals

In other Hikma Pharmaceuticals news, insider Tobias Hestler purchased 7,500 shares of Hikma Pharmaceuticals stock in a transaction dated Monday, August 10th. The stock was acquired at an average price of GBX 1,648 per share, for a total transaction of £123,600. 22.04% of the stock is owned by insiders.

About Hikma Pharmaceuticals

At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly. We are a trusted, reliable partner and dependable source of over 820+ (as of Feb 2026) high-quality generic, specialty and branded pharmaceutical products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe.